Related Experiment Video
Updated: Mar 27, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
From gastric to neuroprotection: pantoprazole mitigates epilepsy via TrkB/BDNF and KCC2 modulation
Arya Kuhu Vishwapriya1, Kamini Verma1, Garima Sharma1
1Department of Pharmacy, Banasthali Vidyapith, Banasthali, 304022, Rajasthan, India.
Abstract:
Epilepsy is generally described as a pathology resulting from an imbalance between excitatory and inhibitory activities. In recent years, neurotrophins have been recognized as key players in the pathophysiology of nervous system diseases. One such neurotrophin, BDNF, and its receptor, TrkB, play critical roles as epileptogenic factors that regulate neuronal hyperexcitability and synaptic plasticity. In this study, we sought to elucidate the exact mechanisms underlying the neuroprotective and antiepileptic effects of pantoprazole. The molecular docking study indicated key interactions of pantoprazole with the TrkB receptor (PDB ID: 4AT3). Furthermore, pantoprazole exhibited notable in vitro TrkB kinase inhibitory activity (IC50 = 24.01 nM) and good cell viability (% viability = 0.0625 mg/ml) against SH-SY5Y cells. Additionally, the protective effects of pantoprazole were assessed in a total oxidative status study, in which PTZ-induced oxidative stress was reduced by ~ 60%. Subsequent observations in the PTZ-induced epilepsy mouse model demonstrated that pantoprazole (5 mg/kg and 10 mg/kg; p.o.; OD) suppresses seizure severity and anxiety-like behavior while enhancing working memory in a dose-dependent manner. Furthermore, a significant increase in antioxidant enzymes such as catalase, reduced glutathione (GSH), and DNA levels, along with degradation of by-products of lipid peroxidation, malondialdehyde (MDA), nitric oxide, and myeloperoxidase (MPO), responsible for causing oxidative stress during epilepsy, occurred after pantoprazole treatment in the PTZ model. The therapy with pantoprazole also increased the mRNA expression of downregulated KCC2 and thereby restored GABAergic inhibition in the synapse and suppressed epilepsy. Together, these findings indicate that pantoprazole exhibits promising neuroprotective and antiepileptic effects via modulation of the TrkB/BDNF pathway and warrant further exploration in clinical subjects for its translation.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Glutamate Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...

